A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Public ClinicalTrials.gov record NCT07623161. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Double-Blind, Randomized Trial Evaluating the Efficacy and Safety of Elritercept (TAK-226) Compared to Placebo in Participants With Myelofibrosis and Anemia on Concurrent Ruxolitinib Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to find out how well elritercept works to improve anemia in participants with myelofibrosis (MF) who are taking ruxolitinib when compared to placebo. Other aims are to learn how elritercept improves anemia compared to placebo; to learn if elritercept reduces tiredness, improves symptoms related to MF, and helps participants do physical activities more easily. The study also aims to find out how elritercept affects the bone marrow, the spleen, and whether participants develop antibodies to the study drug. The study will also check how safe elritercept is compared to placebo, and if elritercept stays safe over a long period of time. Participants will receive study treatment for at least 9 months (36 weeks). After this period, participants who received placebo will have the option to switch to elritercept.
Study identification
- NCT ID
- NCT07623161
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 324 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2026
- Primary completion
- Dec 6, 2029
- Completion
- Mar 29, 2034
- Last update posted
- Jul 22, 2026
2026 – 2034
United States locations
- U.S. sites
- 33
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles Cancer Network | Glendale | California | 91204 | Not yet recruiting |
| Cancer and Blood Specialty Clinic | Whittier | California | 90603 | Not yet recruiting |
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | Not yet recruiting |
| Advanced Research, LLC | Coral Springs | Florida | 33065 | Not yet recruiting |
| Bioresearch Partners | Miami | Florida | 33143 | Not yet recruiting |
| AdventHealth - Cancer Institute - Orlando | Orlando | Florida | 32804-4648 | Not yet recruiting |
| Florida Clinical Trials Group | Tamarac | Florida | 33321 | Not yet recruiting |
| Moffit Cancer Center | Tampa | Florida | 33612 | Not yet recruiting |
| Emory University | Atlanta | Georgia | 30322 | Not yet recruiting |
| Tufts Medical Center | Boston | Massachusetts | 02111 | Not yet recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109-5360 | Not yet recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110 | Not yet recruiting |
| St. Vincent Regional Hospital Cancer Centers | Billings | Montana | 59101 | Not yet recruiting |
| University of New Mexico Comprehensive Cancer Center | Albuquerque | New Mexico | 87102 | Not yet recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | Not yet recruiting |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | Not yet recruiting |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | Withdrawn |
| Novant Health | Winston-Salem | North Carolina | 27103 | Not yet recruiting |
| Atrium Health Wake Forest Baptist | Winston-Salem | North Carolina | 27157-0001 | Withdrawn |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Not yet recruiting |
| Oregon Health and Science University | Portland | Oregon | 97239 | Not yet recruiting |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | Not yet recruiting |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15219 | Not yet recruiting |
| Allegheny Health Network Cancer Institute - West Penn Hospital Location | Pittsburgh | Pennsylvania | 15224 | Not yet recruiting |
| Medical University of South Carolina | Charleston | South Carolina | 29425 | Not yet recruiting |
| Baptist Clinical Research Institute | Memphis | Tennessee | 38120 | Withdrawn |
| Vanderbilt-Ingram Cancer Center (VICC)-Nashville | Nashville | Tennessee | 37232-0021 | Not yet recruiting |
| Next Innovative Clinical Research | Baytown | Texas | 77521 | Not yet recruiting |
| Baylor University Medical Center | Dallas | Texas | 75246 | Not yet recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Not yet recruiting |
| The University of Utah-Huntsman Cancer Institute | Houston | Texas | 77030 | Not yet recruiting |
| LUMI Research | Houston | Texas | 77090 | Recruiting |
| University of Washington | Seattle | Washington | 98109 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 174 non-U.S. sites.
Recently updated Anemia trials
Other public records listing Anemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07725497: A Study of Luspatercept in People With Anemia Recruiting
- NCT07422480: A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions Recruiting
- NCT07671469: Personalized Blood Transfusion Protocol for Cardiac Patients Not yet recruiting
- NCT06042699: Kids With Iron Deficiency and Scoliosis Recruiting
- NCT05800600: Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy Recruiting
- NCT04455841: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07623161, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2026 · Synced Jul 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07623161 live on ClinicalTrials.gov.